Cargando…

Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging

Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaogawa, Shin, Ogawa, Yasuhiro, Morita-Tokuhiro, Shiho, Tsuzuki, Akira, Akima, Ryo, Itoh, Kenji, Morio, Kazuo, Yasunami, Hiroaki, Onogawa, Masahide, Kariya, Shinji, Nogami, Munenobu, Nishioka, Akihito, Miyamura, Mitsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728448/
https://www.ncbi.nlm.nih.gov/pubmed/26703733
http://dx.doi.org/10.3390/cancers8010001
_version_ 1782412112043180032
author Yaogawa, Shin
Ogawa, Yasuhiro
Morita-Tokuhiro, Shiho
Tsuzuki, Akira
Akima, Ryo
Itoh, Kenji
Morio, Kazuo
Yasunami, Hiroaki
Onogawa, Masahide
Kariya, Shinji
Nogami, Munenobu
Nishioka, Akihito
Miyamura, Mitsuhiko
author_facet Yaogawa, Shin
Ogawa, Yasuhiro
Morita-Tokuhiro, Shiho
Tsuzuki, Akira
Akima, Ryo
Itoh, Kenji
Morio, Kazuo
Yasunami, Hiroaki
Onogawa, Masahide
Kariya, Shinji
Nogami, Munenobu
Nishioka, Akihito
Miyamura, Mitsuhiko
author_sort Yaogawa, Shin
collection PubMed
description Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/II or patients refusing surgery. Since surgery was not performed, histological confirmation of the primary tumor region following KORTUC II treatment was not possible. Therefore, to precisely evaluate the response to this new therapy, a detailed diagnostic procedure is needed. The goal of this study was to evaluate the therapeutic response to KORTUC II treatment in patients with stage I/II breast cancer using annual breast contrast-enhanced (CE) magnetic resonance imaging (MRI). Methods: Twenty-one patients with stage I/II breast cancer who were elderly and/or refused surgery were enrolled in this study. All patients underwent MRI prior to and at 3 to 6 months after KORTUC II, and then approximately biannually thereafter. Findings from MRI were compared with those from other diagnostic modalities performed during the same time period. Results: KORTUC II was well tolerated, with minimal adverse effects. All of 21 patients showed a clinically complete response (cCR) on CE MRI. The mean period taken to confirm cCR on the breast CE MRI was approximately 14 months. The mean follow-up period for the patients was 61.9 months at the end of October 2014. Conclusions: The therapeutic effect of BCT using KORTUC II without surgery could be evaluated by biannual CE MRI evaluations. Approximately 14 months were required to achieve cCR in response to this therapy.
format Online
Article
Text
id pubmed-4728448
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-47284482016-02-08 Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging Yaogawa, Shin Ogawa, Yasuhiro Morita-Tokuhiro, Shiho Tsuzuki, Akira Akima, Ryo Itoh, Kenji Morio, Kazuo Yasunami, Hiroaki Onogawa, Masahide Kariya, Shinji Nogami, Munenobu Nishioka, Akihito Miyamura, Mitsuhiko Cancers (Basel) Article Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/II or patients refusing surgery. Since surgery was not performed, histological confirmation of the primary tumor region following KORTUC II treatment was not possible. Therefore, to precisely evaluate the response to this new therapy, a detailed diagnostic procedure is needed. The goal of this study was to evaluate the therapeutic response to KORTUC II treatment in patients with stage I/II breast cancer using annual breast contrast-enhanced (CE) magnetic resonance imaging (MRI). Methods: Twenty-one patients with stage I/II breast cancer who were elderly and/or refused surgery were enrolled in this study. All patients underwent MRI prior to and at 3 to 6 months after KORTUC II, and then approximately biannually thereafter. Findings from MRI were compared with those from other diagnostic modalities performed during the same time period. Results: KORTUC II was well tolerated, with minimal adverse effects. All of 21 patients showed a clinically complete response (cCR) on CE MRI. The mean period taken to confirm cCR on the breast CE MRI was approximately 14 months. The mean follow-up period for the patients was 61.9 months at the end of October 2014. Conclusions: The therapeutic effect of BCT using KORTUC II without surgery could be evaluated by biannual CE MRI evaluations. Approximately 14 months were required to achieve cCR in response to this therapy. MDPI 2015-12-22 /pmc/articles/PMC4728448/ /pubmed/26703733 http://dx.doi.org/10.3390/cancers8010001 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yaogawa, Shin
Ogawa, Yasuhiro
Morita-Tokuhiro, Shiho
Tsuzuki, Akira
Akima, Ryo
Itoh, Kenji
Morio, Kazuo
Yasunami, Hiroaki
Onogawa, Masahide
Kariya, Shinji
Nogami, Munenobu
Nishioka, Akihito
Miyamura, Mitsuhiko
Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging
title Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging
title_full Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging
title_fullStr Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging
title_full_unstemmed Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging
title_short Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging
title_sort serial assessment of therapeutic response to a new radiosensitization treatment, kochi oxydol-radiation therapy for unresectable carcinomas, type ii (kortuc ii), in patients with stage i/ii breast cancer using breast contrast-enhanced magnetic resonance imaging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728448/
https://www.ncbi.nlm.nih.gov/pubmed/26703733
http://dx.doi.org/10.3390/cancers8010001
work_keys_str_mv AT yaogawashin serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT ogawayasuhiro serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT moritatokuhiroshiho serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT tsuzukiakira serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT akimaryo serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT itohkenji serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT moriokazuo serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT yasunamihiroaki serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT onogawamasahide serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT kariyashinji serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT nogamimunenobu serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT nishiokaakihito serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging
AT miyamuramitsuhiko serialassessmentoftherapeuticresponsetoanewradiosensitizationtreatmentkochioxydolradiationtherapyforunresectablecarcinomastypeiikortuciiinpatientswithstageiiibreastcancerusingbreastcontrastenhancedmagneticresonanceimaging